LSL Pharma Group Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 26, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	53	47	40	-	-	-
Market Cap Growth	20.11%	18.48%	-	-	-	-
Enterprise Value	74	61	54	-	-	-
Last Close Price	0.43	0.41	0.48	-	-	-
PE Ratio	19.17	14.28	-	-	-	-
PS Ratio	1.97	2.67	3.99	-	-	-
PB Ratio	2.08	1.90	4.62	-	-	-
P/TBV Ratio	4.77	4.13	-	-	-	-
EV/Sales Ratio	2.77	3.45	5.37	-	-	-
EV/EBITDA Ratio	18.53	35.92	-	-	-	-
EV/EBIT Ratio	52.53	150.86	-	-	-	-
Debt / Equity Ratio	0.85	0.87	1.88	2.84	1.15	1.02
Debt / EBITDA Ratio	5.39	11.30	-	-	47.86	4.08
Net Debt / Equity Ratio	0.85	0.86	1.88	2.84	1.08	0.84
Net Debt / EBITDA Ratio	5.68	12.52	-5.06	-2.52	117.34	3.44
Net Debt / FCF Ratio	-	-6.57	-2.10	-3.61	-6.00	-1.93
Asset Turnover	0.55	0.42	0.35	0.29	0.31	-
Inventory Turnover	-	1.88	2.37	2.92	2.19	-
Quick Ratio	-	0.54	0.18	0.09	0.29	0.35
Current Ratio	1.53	1.59	0.48	0.38	0.89	0.52
Return on Equity (ROE)	12.13%	19.78%	-121.50%	-98.29%	-16.56%	-
Return on Assets (ROA)	1.80%	0.60%	-8.84%	-14.99%	-1.57%	-
Return on Invested Capital (ROIC)	2.94%	1.12%	-18.20%	-31.11%	-3.36%	6.81%
Return on Capital Employed (ROCE)	3.00%	0.90%	-26.00%	-43.10%	-3.30%	11.50%
Earnings Yield	5.26%	7.00%	-21.19%	-	-	-
FCF Yield	-	-6.86%	-19.32%	-	-	-
Buyback Yield / Dilution	-19.11%	-31.18%	-20.94%	-11.78%	-8.34%	-14.88%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.